BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 10864228)

  • 1. New developments and approaches in the platinum arena.
    Judson I; Kelland LR
    Drugs; 2000; 59 Suppl 4():29-36; discussion 37-8. PubMed ID: 10864228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
    Piccart MJ; Lamb H; Vermorken JB
    Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of platinum compounds.
    Hartmann JT; Lipp HP
    Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New platinum agents. A comparison in ovarian cancer.
    Kelland LR; McKeage MJ
    Drugs Aging; 1994 Aug; 5(2):85-95. PubMed ID: 7981487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oxaliplatin: the first DACH platinum in clinical practice].
    Soulié P; Raymond E; Brienza S; Cvitkovic E
    Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin in ovarian cancer.
    Sessa C; ten Bokkel Huinink WW; du Bois A
    Ann Oncol; 1999; 10 Suppl 1():55-7. PubMed ID: 10219454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin and platinum analogues in breast cancer.
    Sledge GW
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):78-82. PubMed ID: 1411630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
    Piccart MJ; Green JA; Lacave AJ; Reed N; Vergote I; Benedetti-Panici P; Bonetti A; Kristeller-Tome V; Fernandez CM; Curran D; Van Glabbeke M; Lacombe D; Pinel MC; Pecorelli S
    J Clin Oncol; 2000 Mar; 18(6):1193-202. PubMed ID: 10715288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies against prostate cancer--Pt(II)-based chemotherapy.
    Matos CS; de Carvalho AL; Lopes RP; Marques MP
    Curr Med Chem; 2012; 19(27):4678-87. PubMed ID: 22856665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin in the treatment of ovarian cancer.
    Alberts DS; Mason-Liddil N
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of carboplatin in ovarian cancer. Current results and thoughts for the future.
    Ozols RF
    Acta Obstet Gynecol Scand Suppl; 1992; 155():75-7. PubMed ID: 1502894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin in the first-line chemotherapy of ovarian cancer.
    Alberts DS; Canetta R; Mason-Liddil N
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.